iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021
September 20 2021 - 6:30AM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of
next-generation biopharmaceuticals and pioneer of the sustainable,
plant-based
FastPharming Manufacturing System®,
announced today that it will report its fiscal fourth quarter and
full year 2021 financial results before market open on Monday,
September 27, 2021. iBio management will host a webcast and
conference call at 8:30 a.m. Eastern Time to discuss the results
and provide a corporate update.
The live and archived webcast may be accessed on
the Company’s website at www.ibioinc.com under “News and Events” in
the Investors section. The live call can be accessed by dialing
(833) 672-0651 (domestic) or (929) 517-0227 (international) and
referencing conference code: 7159935.
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals and a pioneer in sustainable, plant-based
biologics manufacturing.
Its FastPharming System® combines
vertical farming, automated hydroponics, and novel glycosylation
technologies to rapidly deliver high-quality monoclonal antibodies,
vaccines, bioinks and other proteins. iBio is developing
proprietary biopharmaceuticals for the treatment of cancers, as
well as fibrotic and infectious diseases. The Company’s subsidiary,
iBio CDMO LLC,
provides FastPharming Contract
Development and Manufacturing Services along with
Glycaneering Development Services™ for
advanced recombinant protein design. For more information, visit
www.ibioinc.com.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2024 to May 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From May 2023 to May 2024